Neurocrine
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.
NBIX Key Statistics
Stock Snapshot
As of today, Neurocrine(NBIX) shares are valued at $133.70. The company's market cap stands at 13.36B, with a P/E ratio of 28.03.
During the trading session on 2026-04-08, Neurocrine(NBIX) shares reached a daily high of $134.00 and a low of $128.90. At a current price of $133.70, the stock is +3.7% higher than the low and still -0.2% under the high.
Trading activity shows a volume of 1.21M, compared to an average daily volume of 1.14M.
The stock's 52-week range extends from a low of $84.23 to a high of $160.18.
The stock's 52-week range extends from a low of $84.23 to a high of $160.18.
NBIX News
Investors in Neurocrine Biosciences, Inc. (Symbol: NBIX) saw new options become available today, for the December 2027 expiration. One of the key data points th...
RBC Capital lowered the firm’s price target on Neurocrine (NBIX) to $176 from $177 and keeps an Outperform rating on the shares as part of the firm’s broader re...
Neurocrine Biosciences, ticker NasdaqGS:NBIX, held an official M&A call regarding Soleno Therapeutics. The call focused on a potential transaction involving So...
Analyst ratings
87%
of 30 ratingsMore NBIX News
In a report released yesterday, Sean Laaman from Morgan Stanley maintained a Hold rating on Neurocrine, with a price target of $173.00. Easter Sale - 70% Off Ti...
Analyst Tazeen Ahmad of Bank of America Securities reiterated a Buy rating on Neurocrine, boosting the price target to $199.00. Easter Sale - 70% Off TipRanks U...
Soleno Therapeutics (NASDAQ:SLNO), a rare-disease drug developer, closed Monday at $52.26, up 32.31%. The stock’s move reflects Neurocrine Biosciences’ (NASDAQ:...
On news that Soleno Therapeutics (SLNO +32.31%) has agreed to be acquired, investors piled into the company's shares on Monday. This left the commercial-stage b...
...
Analyst Ami Fadia from Needham maintained a Buy rating on Neurocrine and keeping the price target at $185.00. Unlock hedge fund-level data and powerful investi...
After last week’s volatility, futures are modestly higher. Markets are starting the week in a cautious holding pattern, caught between tentative optimism and ve...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.